Shares in Isofol Medical AB dropped by 27% on Dec. 6 as the company informed investors that its ongoing phase III trial of arfolitixorin in metastatic colorectal cancer would not reach the predefined ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback